Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza

ABSTRACT The differential antibody response measured by the commonly used hemagglutination inhibition (HI) and microneutralization (MN) assays in patients with natural infection and vaccination has not been fully assessed. HI and conventional MN (CMN) assays were performed on sera from 651 patients with natural infection by pandemic H1N1 2009 influenza virus and on sera from 567 recipients of the corresponding vaccine. Surprisingly, the overall seroprotection rates determined by CMN and HI assays in vaccine recipients were only 44.8 and 35.1%, respectively. Antibody titers measured by the CMN assay was significantly higher than that obtained by HI assay in vaccine recipients aged ≥50 years, but these titers were not significantly different among younger vaccine recipients. In contrast, the HI titer was greater than the CMN titer for the age group from 16 to 29 years but was not significantly different in other age groups for natural infection. Lower antibody levels were found in both naturally infected patients and immunized recipients in the older than in the younger age groups, but naturally infected patients exhibited higher HI and CMN titers than did the corresponding vaccine recipients. In addition, we developed a rapid fluorescent focus microneutralization (FFMN) assay to test sera from naturally infected patients. The FFMN assay has a better correlation with CMN than with HI (ρ = 0.810 versus 0.684), which is expected of neutralizing antibody mainly targeted toward the inhibition of viral entry into cells. The higher antibody level elicited by natural infection than by vaccination may be related to differences between antigen presentation by the intramuscular route of vaccination and mucosal viral replication in mucosal cells of the respiratory tract.

[1]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Y. Hsieh,et al.  Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. , 2011, Vaccine.

[3]  J. Noh,et al.  Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. , 2011, Vaccine.

[4]  K. To,et al.  The Lower Serum Immunoglobulin G2 Level in Severe Cases than in Mild Cases of Pandemic H1N1 2009 Influenza Is Associated with Cytokine Dysregulation , 2010, Clinical and Vaccine Immunology.

[5]  W. Lim,et al.  Sero‐immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong , 2010, Journal of medical virology.

[6]  W. Liu,et al.  Clinical and immunological characteristics of patients with 2009 pandemic influenza A (H1N1) virus infection after vaccination. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[8]  Kazuo Suzuki,et al.  Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health‐care workers of a university hospital in Japan , 2010, Microbiology and immunology.

[9]  I. Hung,et al.  Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection , 2010, Transfusion.

[10]  A. Cook,et al.  Serological Response in RT-PCR Confirmed H1N1-2009 Influenza A by Hemagglutination Inhibition and Virus Neutralization Assays: An Observational Study , 2010, PloS one.

[11]  K. To,et al.  Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[13]  G. Poggensee,et al.  Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  Samson S. Y. Wong,et al.  Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Permezel,et al.  Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Blatter,et al.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2010, The Lancet.

[17]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[18]  S. Wurtzer,et al.  Enhancement of the Influenza A Hemagglutinin (HA)-Mediated Cell-Cell Fusion and Virus Entry by the Viral Neuraminidase (NA) , 2009, PloS one.

[19]  M. Greenberg,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[20]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[21]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[22]  J. Peiris,et al.  Viral load in patients infected with pandemic H1N1 2009 influenza A virus , 2009, Journal of medical virology.

[23]  Robert Schechter,et al.  Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. , 2009, JAMA.

[24]  T. Toyoda,et al.  Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. , 2009, Biochemical and biophysical research communications.

[25]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[26]  C. Siegrist,et al.  B-cell responses to vaccination at the extremes of age , 2009, Nature Reviews Immunology.

[27]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[28]  Yanqing Ding,et al.  Development of an Antigen Capture Immunoassay Based on Monoclonal Antibodies Specific for Dengue Virus Serotype 2 Nonstructural Protein 1 for Early and Rapid Identification of Dengue Virus Serotype 2 Infections , 2008, Clinical and Vaccine Immunology.

[29]  M. Eichelberger,et al.  FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. , 2008, Vaccine.

[30]  R. G. Das,et al.  Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. , 2007, Vaccine.

[31]  K. Yuen,et al.  Serotype 1-Specific Monoclonal Antibody-Based Antigen Capture Immunoassay for Detection of Circulating Nonstructural Protein NS1: Implications for Early Diagnosis and Serotyping of Dengue Virus Infections , 2006, Journal of Clinical Microbiology.

[32]  T. Sakai,et al.  Roles of neuraminidase in the initial stage of influenza virus infection. , 2006, Microbes and infection.

[33]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[34]  H. Klenk,et al.  Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium , 2004, Journal of Virology.

[35]  G. Duke,et al.  Development of an efficient fluorescence-based microneutralization assay using recombinant human cytomegalovirus strains expressing green fluorescent protein. , 2004, Journal of virological methods.

[36]  A. Charlett,et al.  Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. , 2004, Virus research.

[37]  K G Nicholson,et al.  Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin , 2003, Journal of medical virology.

[38]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[39]  G. Ligthart,et al.  Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay , 1998, Journal of medical virology.

[40]  M. Harmsen,et al.  Comparison of Neutralizing and Hemagglutination-Inhibiting Antibody Responses to Influenza A Virus Vaccination of Human Immunodeficiency Virus-Infected Individuals , 1998, Clinical Diagnostic Laboratory Immunology.

[41]  B. Murphy,et al.  Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors , 1992, Journal of clinical microbiology.

[42]  Sera,et al.  Distinct glycoprotein inhibitors of influenza A virus in different animal sera , 1991, Journal of virology.

[43]  G. Ada,et al.  Persistence of influenza virus-specific antibody-secreting cells and B-cell memory after primary murine influenza virus infection. , 1987, Cellular immunology.

[44]  T. Cate,et al.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement , 1980, Journal of clinical microbiology.

[45]  N. Grist.  Pandemic influenza 1918. , 1979, British medical journal.

[46]  J. Davies,et al.  Natural infection with influenza A (H3N2). The development, persistence and effect of antibodies to the surface antigens , 1976, Journal of Hygiene.

[47]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[48]  K. To,et al.  Title Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H 1 N 1 2009 , 2010 .

[49]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .

[50]  M. Mazzilli,et al.  A nonneutralizing human IgM monoclonal antibody inhibiting hemagglutination of H3N2 influenza A strains. , 1986, Hybridoma.

[51]  C W Potter,et al.  Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.

[52]  C. Paniker,et al.  Non-specific inhibitors of influenza viruses in normal sera. , 1960, Bulletin of the World Health Organization.